# Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach

> **NCT05295992** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Varian, a Siemens Healthineers Company** · enrollment: 110 (estimated)

## Conditions studied

- Muscle-Invasive Bladder Carcinoma

## Interventions

- **DEVICE:** Varian Ethos Adaptive Radiation Therapy

## Key facts

- **NCT ID:** NCT05295992
- **Lead sponsor:** Varian, a Siemens Healthineers Company
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-15
- **Primary completion:** 2026-12
- **Final completion:** 2027-03
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05295992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05295992, "Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05295992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*